Skip to main content

Forget Volmageddon: Gammageddon Is Coming…

“Volmageddon” entered the financial lexicon in February 2018, a word that blends destructive connotations of Armageddon with the explosive dynamics of market volatility. A fitting new word, if ever there was one, to describe a one-day event that had no forewarning and no trigger, yet in a few hours, destroyed a whole substratum of investors – those that played the short volatility carry trade. 

Selling volatility has always been a very seductive trade, and with the advent of the VIX futures market, it has opened up to a broader investor base. However, as we scan the investment world today, the rise of the zero-day option market has led many to suggest that this black swan event may return, and this time, the collateral damage could spread beyond a niche within the volatility market. But will history rhyme or repeat?

Enter 'Gammageddon'

Volatility is a major component in the pricing of any option, and so for any short option trade, the investor will be short volatility. As volumes have exploded in this market, there is a growing consensus that a build-up in short volatility exposure is a disaster waiting to happen, that a volatility short squeeze could appear from nowhere in a nasty repeat of Volmageddon. 

The risk of a blowup is genuine, but it will not be in vol space but in the gamma space. A “Gammageddon”, if you will.

Toby Hayes
Toby Hayes

For an unhedged option exposure, investors’ biggest risk is delta (the sensitivity of the option to the underlying share or index price), and when the option is very short-dated, gamma (rate of change of delta) is a close second.

For these short-dated unhedged options, a move in implied volatility has very little impact on investors’ portfolios relative to the loss that can occur due to the delta/gamma risk. A sudden move, or worse - an accelerating move, in the S&P price can be disastrous. The rush to close out positions, enter hedges, etc., from a sudden move is where the problem would originate. This is not a volatility problem but a gamma problem.

Implied volatility levels in the one-day options market regularly double and often spike intraday with no associated short squeeze dynamics. If this were to happen every day in the VIX market, no investors would still be alive to play. Yes, market participants in the zero-day options market are short volatility from a technical perspective, but this risk is inconsequential when compared to the short gamma profile. 

The volatility of the one-day options market rises towards the end of the day, as investors selling options near to the close require larger premiums since even a small move in the S&P can lead to large volumes of options expiring ITM or OTM. Sellers need to be paid more as the market draws to a close as this is when the gamma risk is highest, and hence, the average price (or implied volatility) of the option market rises. 

These large swings in intraday volatility do not phase market participants, because investors are selling gamma, not volatility, even though they perhaps don’t realise it. 

How could ‘Gammageddon’ play out?

As we saw with Volmageddon, volatility pricing can sometimes be independent of what is going on with wider equity markets. However, gamma risk is always dependent on the underlying share/index price, as the equity price will determine whether the option expires worthless or in the money. Hence, gamma risk is always path-dependent on the underlying share/index price.

This path dependency implies the investors' gamma risk will change throughout the day as the underlying index price moves. So will the (opposite) gamma risk of those market participants on the other side of the trade – usually taken by brokers/banks.

Typically, brokers start the day by being long gamma, and if the market starts falling, they will reduce their gamma position by buying equity futures. This gamma hedging will tend to dampen any small S&P moves while also creating a very noticeable intraday reversion effect (buy the dip). 

If a negative gamma profile develops across all the brokers/banks, their aggregate gamma hedging activity could switch from ‘buying the dip’ to chasing the momentum. They could all start selling/buying in the direction of the market simultaneously. 

Each broker's gamma profiles (i.e. how their gamma risk changes as the index price moves) on any given day will always be different, and it is impossible to know whether this path dependency aligns across the street. Theoretically, at least, an alignment would most likely occur after a gap risk event (a sudden macro shock). In such an event, the mean reversion dampening effect that brokers/banks usually provided by their hedging activity could quickly switch into a downward momentum chase. 

Doom loop

Panicked option traders would add to this accelerating doom loop, a gamma short squeeze would ensue and “Gammageddon” would be born.

Volatility selling is just too profitable to ignore, and after every short volatility squeeze, investors always return time and time again. We see that in the aftermath of Volmageddon, some retail speculators have returned to the VIX market, yet the volume of the short VIX carry trade is a shadow of its former self. Retail investors have a new toy to play with: gamma selling in the zero-day options market.

Gamma selling is equally just as profitable (and a very similar trade in terms of return profile), and so far, so good - no blowups. With no collective memory of financial loss, seductive returns and a new crowd of speculative retail investors, it seems that gamma selling in zero-day options has cannibalised the short interest in VIX.

The trade is different, but the story is the same: only time will tell if Gammageddon takes its place in the pantheon of financial disasters.


Toby Hayes is Portfolio Manager of the Trium Alternative Growth Fund at Trium Capital


The views expressed in this article are those of the author and do not necessarily reflect the views of AlphaWeek or its publisher, The Sortino Group

Content role

© The Sortino Group Ltd

All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or scanning or otherwise, except under the terms of the Copyright, Designs and Patents Act 1988 or under the terms of a licence issued by the Copyright Licensing Agency or other Reprographic Rights Organisation, without the written permission of the publisher. For more information about reprints from AlphaWeek, click here.